AQS

Aequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology Expertise

Retrieved on: 
Wednesday, August 25, 2021
Cell death, Revision, Adult, FRCS, Pediatric surgery, Master of Science, Retina, Research, Safety, Risk, Pediatrics, AMD, OTCQB, University, Lists of diseases, Ophthalmology, Doctor of Philosophy, Humanitarian use licenses, Therapy, Forward-looking statement, SEDAR, Technology, Degenerative disease, MD, Legislation, Disease, AQS, Retinal degeneration (rhodopsin mutation), Company, Retinal degeneration, Acquisition, GLOBE, Patient, MCH, Lipofuscin, Pharmaceutical industry

REV-0100 is a potential therapy for patients with Stargardt disease that is designed to bind and clear a toxiclipidcalled lipofuscin.

Key Points: 
  • REV-0100 is a potential therapy for patients with Stargardt disease that is designed to bind and clear a toxiclipidcalled lipofuscin.
  • Aequus Pharmaceuticalsand Dr.Koenekooplook forward to working closelywithreVision Therapeutics to support the development of REV-0100for Stargardt disease.
  • Stargardt disease is also called Stargardt macular dystrophy, juvenile macular degeneration, or fundusflavimaculatus.
  • Stargardt disease is one of several but the most common cause of genetic disorders that cause juvenile macular degeneration.

Aequus and reVision to Collaborate on Stargardt Disease Program

Retrieved on: 
Tuesday, August 17, 2021
Cell death, Company, AMD, OTCQB, Revision, Priority review, Legislation, Program, Lists of diseases, Genetic disorder, Macular degeneration, Technology, Orphan drug, Acquisition, Cornell University, GLOBE, Ophthalmology, Retina, Severe cognitive impairment, Research, Food, Disease, Humanitarian use licenses, Therapy, Perception, Forward-looking statement, AQS, Review, Safety, Risk, Patient, SEDAR, CEO, US Foods, Lipofuscin, Weill Cornell Medicine, Patent, GMP, Pharmaceutical industry

VANCOUVER, British Columbia and RIDGEWOOD, N.J., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (Aequus) and reVision Therapeutics, Inc. (reVision) announce a collaboration on the development of a therapy for Stargardt disease.

Key Points: 
  • VANCOUVER, British Columbia and RIDGEWOOD, N.J., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (Aequus) and reVision Therapeutics, Inc. (reVision) announce a collaboration on the development of a therapy for Stargardt disease.
  • The agreement allows Aequus the option to acquire North American commercial rights to REV-0100, reVisions proprietary Stargardt disease program.
  • reVision is thus poised to demonstrate the benefit of reducing levels of lipofuscin to alter the course of Stargardt disease progression.
  • The US Food and Drug Administration has already designated REV-0100 as an Orphan Drug and a Rare Pediatric Disease Drug forthe treatment of Stargardt disease.

Aequus and reVision to Collaborate on Stargardt Disease Program

Retrieved on: 
Tuesday, August 17, 2021
Cell death, Company, AMD, OTCQB, Revision, Legislation, Program, Lists of diseases, Genetic disorder, Macular degeneration, Priority review, Technology, Orphan drug, Acquisition, Cornell University, Ophthalmology, Retina, Severe cognitive impairment, Research, Food, Disease, Risk, Humanitarian use licenses, Therapy, Perception, Forward-looking statement, AQS, Review, Safety, Patient, SEDAR, CEO, US Foods, Lipofuscin, Weill Cornell Medicine, Patent, GMP, Pharmaceutical industry

VANCOUVER, BCand RIDGEWOOD, N.J., Aug. 17, 2021 /PRNewswire/ -- Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) ("Aequus") and reVision Therapeutics, Inc. ("reVision") announce a collaboration on the development of a therapy for Stargardt disease.

Key Points: 
  • VANCOUVER, BCand RIDGEWOOD, N.J., Aug. 17, 2021 /PRNewswire/ -- Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) ("Aequus") and reVision Therapeutics, Inc. ("reVision") announce a collaboration on the development of a therapy for Stargardt disease.
  • The agreement allows Aequus the option to acquire North American commercial rights to REV-0100, reVision's proprietary Stargardt disease program.
  • reVision is thus poised to demonstrate the benefit of reducing levels of lipofuscin to alter the course of Stargardt disease progression.
  • The US Food and Drug Administration has already designated REV-0100 as an Orphan Drug and a Rare Pediatric Disease Drug forthe treatment of Stargardt disease.

Raytheon delivers 10th AN/AQS-20C minehunting sonar to US Navy

Retrieved on: 
Wednesday, January 15, 2020
Naval warfare, Weapons, Anti-submarine warfare, Sonar, Synthetic aperture radar, Submarine warfare, Synthetic aperture sonar, AQS, Naval mine, RTN

WASHINGTON, Jan. 15, 2020 /PRNewswire/ --Raytheon Company (NYSE: RTN) delivered its 10th AN/AQS-20C minehunting sonar system to the U.S. Navy.

Key Points: 
  • WASHINGTON, Jan. 15, 2020 /PRNewswire/ --Raytheon Company (NYSE: RTN) delivered its 10th AN/AQS-20C minehunting sonar system to the U.S. Navy.
  • The AN/AQS-20C comprises five distinct sonars, including a synthetic aperture sonar that provides the highest possible resolution for acoustic identification.
  • The system detects, classifies, localizes, and identifies mines on the seabed, near-bottom moored mines, volume mines, and near-surface mines.
  • "Delivery of the 10th towed body brings this critical autonomous technology one step closer to IOC."